The US Food and Drug Administration has approved a follow-on, or biosimilar, medicine for diabetes from Sanofi SA that is intended to improve the control of blood sugar in children and adults with both Type 1 and Type 2 forms of the disease.
Hookipa Biotech AG has raised €50 million in an oversubscribed Series C financing to support the clinical development of vaccines for infectious diseases and cancer. The round was led by an undisclosed US public investment fund.
Belgium-based Aelin Therapeutics has received €27 million in Series A financing from a syndicate of investors to develop a new class of antibiotics against human targets that thus far have been undruggable. The company is a spin-out of the VIB research institute.
OSE Immunotherapeutics SA is set to resume recruitment into a Phase 3 trial of patients with non-small cell lung cancer (NSCLC) following a pause in June to enable investigators to have more time to assess the effect of the treatment which is a neoantigen therapy called Tedopi.
The French specialist pharma company Advicenne Pharma SA raised €27 million in an initial public offering (IPO) of its shares on the Paris Euronext exchange on 4 December to advance its pipeline of drugs for orphan renal and neurological diseases.
Medigene has raised its revenue forecast for 2017 following an agreement to sell its product for the treatment of genital wards, Veregen, to a subsidiary of Novartis. The sale finishes the disposal of its legacy products, enabling the company to focus on immunotherapy.
GW Pharmaceuticals Plc said it intends to issue $225 million worth of its shares on the US Nasdaq market subject to market conditions and investor appetite.
GW Pharmaceutical Plc, which is developing cannabinoid medicines for epilepsy and other diseases of the central nervous system, reported a 20.1% decline in revenue to £8.2 million for the fiscal year ended 30 September 2017, while its operating loss soared by more than 70% to £153.3 million.
Semma Therapeutics Inc, a company founded by the Harvard University Professor Douglas Melton, has raised $114 million in an oversubscribed Series B financing round to bring a stem cell therapy for Type1 diabetes into the clinic.
MorphoSys AG has increased its financial guidance for 2017 in the wake of a licensing deal with I-Mab Biopharma, a biologics company based in Shanghai, China. The agreement gives I-Mab the right to develop the German company’s antibody for multiple myeloma for the Chinese market.